Muscarinic Agonism in Schizophrenia: Mechanism and Strategy

Dr. Jackson introduces the muscarinic system and xanomeline-trospium chloride, FDA approved in 2024 as a new, non-D2-blocking mechanism with potential benefit for positive symptoms and cognition. Dr. Alva calls it a genuine paradigm shift, explaining it indirectly modulates dopamine presynaptically rather than blocking receptors postsynaptically. Because muscarinic agonists also engage peripheral M2 and M3 receptors, the trospium component can cause cholinergic-type side effects, so patients need preparation for early nausea or vomiting to avoid premature discontinuation. Dr. Jackson notes that older agents carry irreversible long-term risks like tardive dyskinesia, then asks how the panel approaches switching versus adding this new option.

Dr. Hunter explains he typically adds xanomeline-trospium onto a patient's existing regimen rather than cross-titrating, citing fear among patients and families despite supportive data. This often yields additional symptom reduction, even atop agents like clozapine, before he tapers the original medication, alongside proactively scheduled antiemetics so patients never associate the drug with nausea. Dr. Hicks shares that she used an analogous titrate-up, taper-down strategy with her daughter's long-acting injectable, with strong results. Dr. Alva notes trials studied monotherapy, but real-world use often adds the drug onto an existing long-acting injectable, and he has transitioned some patients off clozapine entirely. Spencer describes learning that slow titration undermined both efficacy and tolerability; he now starts at 50 mg for a week before advancing to 125 mg, with better results. Dr. Alva now follows the original trial titration schedule and notes a persistent awareness gap among colleagues.

Dr. Jackson turns to dosing mechanics, weighing discontinuation against careful tapering, noting most trial patients reached the full target dose. Side effects can guide component-specific adjustments: more cholinergic, GI-type symptoms may call for a higher xanomeline dose, while anticholinergic effects like dry mouth suggest caution before raising the trospium dose. Dr. Alva recommends ginger root tea and flags avoiding food with this medication, since food can blunt trospium absorption.

The next episode in this series, "The Case for Early Muscarinic Therapy in Schizophrenia," shows what these strategies look like in outcomes, and makes the case for starting even sooner.